[go: up one dir, main page]

WO2012020021A9 - Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques - Google Patents

Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques Download PDF

Info

Publication number
WO2012020021A9
WO2012020021A9 PCT/EP2011/063702 EP2011063702W WO2012020021A9 WO 2012020021 A9 WO2012020021 A9 WO 2012020021A9 EP 2011063702 W EP2011063702 W EP 2011063702W WO 2012020021 A9 WO2012020021 A9 WO 2012020021A9
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
cancer
treatment
inflammation
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/063702
Other languages
English (en)
Other versions
WO2012020021A1 (fr
Inventor
Dirk Classen-Houben
Bernhard Kueenburg
Paul Kosma
Ulrich Jordis
Laszlo Czollner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onepharm Research and Development GmbH
Original Assignee
Onepharm Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onepharm Research and Development GmbH filed Critical Onepharm Research and Development GmbH
Priority to EP11740948.2A priority Critical patent/EP2632933A1/fr
Publication of WO2012020021A1 publication Critical patent/WO2012020021A1/fr
Publication of WO2012020021A9 publication Critical patent/WO2012020021A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés de formule générale (I), dans laquelle R3a à R31 et X sont tels que définis dans la revendication 1, qui sont appropriés pour le traitement et/ou la prévention de maladies inflammatoires chroniques, des maladies auto-immunes, des maladies de la peau, des maladies des os, des maladies métaboliques, des maladies infectieuses et du cancer.
PCT/EP2011/063702 2010-08-10 2011-08-09 Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques Ceased WO2012020021A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11740948.2A EP2632933A1 (fr) 2010-08-10 2011-08-09 Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172411.0 2010-08-10
EP10172411 2010-08-10

Publications (2)

Publication Number Publication Date
WO2012020021A1 WO2012020021A1 (fr) 2012-02-16
WO2012020021A9 true WO2012020021A9 (fr) 2012-05-10

Family

ID=44629815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/063702 Ceased WO2012020021A1 (fr) 2010-08-10 2011-08-09 Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques

Country Status (2)

Country Link
EP (1) EP2632933A1 (fr)
WO (1) WO2012020021A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276468B (zh) * 2018-03-13 2019-12-31 中国农业科学院兰州畜牧与兽药研究所 一种甘草次酸酯及其制备方法和在制备抗病毒药物中的应用
WO2019222800A1 (fr) * 2018-05-21 2019-11-28 Hudson Institute of Medical Research Procédés pour le traitement ou la prévention de maladies auto-immunes ou auto-inflammatoires
JP7735185B2 (ja) * 2019-02-07 2025-09-08 アルデリックス， インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体

Also Published As

Publication number Publication date
EP2632933A1 (fr) 2013-09-04
WO2012020021A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
CA2871471C (fr) Inhibiteurs d'adn pk
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MY164731A (en) Compound
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
TN2012000369A1 (en) 5-alkynyl-pyrimidines
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
PH12014501718A1 (en) Novel therapeutic agents
IN2012MN02591A (fr)
EP4275756A3 (fr) Dérivés de bipyrazole servant d'inhibiteurs de jak
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
WO2014096425A3 (fr) Promédicaments de fumarate de monométhyle (mmf)
IN2015DN01119A (fr)
MY183974A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
EP3133073A3 (fr) Inhibiteurs d'iap
MX2012013607A (es) Polisacarido de las semillas de tamarindo para usarse en el tatamiento de enfermedades inflamatorias.
HK1201067A1 (en) Sialic acid analogs
WO2012020021A9 (fr) Analogues amine d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'inflammation, des maladies infectieuses, du cancer, des maladies auto-immunes, des maladies de la peau, des maladies des os et des maladies métaboliques
WO2013071400A8 (fr) Conjugués d'apocynine-acide lipoïque et leurs utilisations
WO2012061012A3 (fr) Analogues 4-amino-2h-pyran-2-one en tant qu'agents anticancéreux
WO2013033602A3 (fr) Amides d'acide gras, compositions et procédés d'utilisation
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740948

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011740948

Country of ref document: EP